MIAMI, Oct. 6, 2020 /PRNewswire-PRWeb/ -- DNA® BIOPHARM (DNA®), today announced the U.S. launch of its female urinary incontinence supplement, FEMAXEEN®, which helps to support a healthy bladder and urinary tract health.
In the United States, more than four in 10 women 65 and older have urinary incontinence. Of approximately 75 million women over the age of 40 (nearly 25 million) suffer from urinary incontinence from mild to severe with many of them choosing adult diapers as their solution. With FEMAXEEN®, women can take control of their bladder again without choosing a solution that might otherwise make them feel shameful.
"As women get older, bladder control and urinary tract health are among their top concerns," said Oscar del Cid, President and CEO of DNA®. "We want to provide them a less embarrassing solution to their incontinence and that is exactly what FEMAXEEN® does; it gives our customers a safe, tested treatment using natural ingredients to help support a healthy bladder. After all, don't forget that 'diapers are for babies'."
A complete solution for women's incontinence, FEMAXEEN® has been tested and evaluated through a randomized, double-blind, placebo-controlled study with findings citing a 45.3% reduction in incontinence within two months. The supplement is made with pollen extracts (UriCyTonin®), pumpkin seed extract, and Vitamin E.
Now available in the U.S., FEMAXEEN® can be purchased without a prescription.
To learn more about FEMAXEEN® visit https://femaxeen.com.
About FEMAXEEN®
FEMAXEEN® is distributed by DNA Pharm® as s dietary supplement that helps support lower urinary tract health. A complete solution for women's incontinence, FEMAXEEN® has been tested and evaluated through a randomized, double-blind, placebo-controlled study with findings citing a 45.3% reduction in incontinence within two months. Now available in the U.S., FEMAXEEN® can be purchased without a prescription.
About DNA BIOPHARM ®
Founded in 1992, DNA® has done business in over 25 countries, covering six continents, and currently operating in America (Miami), Mexico (Mexico City) Europe (Budapest, Hungary), and Africa (Cape Town, South Africa). In 2013, DNA Mexico became one of the largest distributors of The Day After Pill after introducing the pill in 2003 and selling about 30,000,000 units within a 10-year period. Today, DNA® continues to manufacture and distribute a comprehensive line of products that target a wide range of health issues ranging from immune deficiency, psoriasis, acne, adrenal stability, incontinence, and more. DNA® is poised to continue great leaps forward with their tradition of growth, quality, and service worldwide.
SOURCE DNA BIOPHARM
Share this article